CDK12 and neoplasm: Integrating inflammatory biomarkers with PSA or mpMRI may enhance diagnostic accuracy and guide personalized immunotherapeutic strategies, such as targeting NF-κB or tumor-associated macrophages via CDK12/13 inhibition or CD47 blockade.